Literature DB >> 11602692

Discriminative stimulus effects of intravenous heroin and its metabolites in rhesus monkeys: opioid and dopaminergic mechanisms.

D M Platt1, J K Rowlett, R D Spealman.   

Abstract

Heroin has characteristic subjective effects that contribute importantly to its widespread abuse. Drug discrimination procedures in animals have proven to be useful models for investigating pharmacological mechanisms underlying the subjective effects of drugs in humans. However, surprisingly little information exists concerning the mechanisms underlying the discriminative stimulus (DS) effects of heroin. This study characterized the DS effects of heroin in rhesus monkeys trained to discriminate i.v. heroin from saline. In drug substitution experiments, heroin, its metabolites 6-monoacetylmorphine, morphine, morphine-6-glucuronide, and morphine-3-glucuronide, and the mu-agonists fentanyl and methadone engendered dose-dependent increases in heroin-lever responding, reaching average maximums of >80% (full substitution) at doses that did not appreciably suppress response rate. In contrast, the delta-agonist SNC 80, the kappa-agonist spiradoline, and the dopamine uptake blockers/releasers cocaine, methamphetamine, and GBR 12909 did not engender heroin-like DS effects regardless of dose. In antagonism studies, in vivo apparent pA2 and pK(B) values for naltrexone combined with heroin, morphine, and 6-monoacetylmorphine (8.0-8.7) were comparable with those reported previously for naltrexone antagonism of prototypical mu-agonists. The results show that the DS effects of heroin are pharmacologically specific and mediated primarily at mu-opioid receptors. Moreover, the acetylated and glucuronated metabolites of heroin appear to play significant roles in these effects. Despite previous speculation that morphine-3-glucuronide lacks significant opioid activity, it substituted fully for heroin in our study, suggesting that it can exhibit prominent mu-agonist effects in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602692

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  Human Drug Discrimination: Elucidating the Neuropharmacology of Commonly Abused Illicit Drugs.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Curr Top Behav Neurosci       Date:  2018

Review 2.  Developing a vaccine against multiple psychoactive targets: a case study of heroin.

Authors:  G Neilm Stowe; Joel E Schlosburg; Leandro F Vendruscolo; Scott Edwards; Kaushik K Misra; Gery Schulteis; Joseph S Zakhari; George F Koob; Kim D Janda
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

3.  The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats.

Authors:  Snjezana Lelas; Kim L Zeller; Kathryn A Ward; John F McElroy
Journal:  Psychopharmacology (Berl)       Date:  2003-02-18       Impact factor: 4.530

4.  Asymmetric generalization and interaction profiles in rhesus monkeys discriminating intravenous cocaine or intravenous heroin from vehicle.

Authors:  Donna M Platt; James K Rowlett; Roger D Spealman
Journal:  J Pharmacol Exp Ther       Date:  2009-12-04       Impact factor: 4.030

Review 5.  Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression.

Authors:  M J Finley; C M Happel; D E Kaminsky; T J Rogers
Journal:  Cell Immunol       Date:  2008-02-14       Impact factor: 4.868

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.